Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581698 · ClinicalTrials.gov registry record
Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 876
- Enrollment target
NCT00581698: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00581698 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 876 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00581698 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 876 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether we can consistently identify the first lymph node (the "sentinel node") draining your melanoma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 876 participants |
| Start Date | 1991-01 |
| Est. Completion | 2009-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00581698
The ClinicalTrials.gov registry entry for NCT00581698 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 876 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00581698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00581698 about?
NCT00581698 is a clinical study titled "Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue". The purpose of this study is to determine whether we can consistently identify the first lymph node (the "sentinel node") draining your melanoma.
What is the current status of trial NCT00581698?
This trial is currently completed. The enrollment target is 876 participants. The study started on 1991-01. Estimated completion is 2009-09.
Who is sponsoring clinical trial NCT00581698?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.